---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-056017"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:49:26.099039+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed

## Summary
- Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).
- GAAP diluted EPS $0.78; non-GAAP adjusted diluted EPS $1.22 (+13% YoY); includes $0.05 IPR&D/milestone charge.
- Women's Health revenue +11% on Nexplanon (+34% ex-FX); Biosimilars +46% led by Hadlima ($30M vs $5M).
- Adjusted EBITDA $538M, margin 33.2%; full-year 2024 financial guidance ranges affirmed.

## SEC filing metadata
- accession: 0001104659-24-056017
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/0001104659-24-056017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/tm2413293d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-056017
- JSON: https://secwatch.observer/filing/0001104659-24-056017.json
- Plain text: https://secwatch.observer/filing/0001104659-24-056017.txt

## Key facts
- Earnings Releases
  Organon & Co. reported the first quarter ended March 31, 2024 results: revenue $1,622 million, net income $201 million, EPS $0.78. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $1,622 million
  - Net income: $201 million
  - EPS: $0.78
  - Guidance: reaffirmed
  - Result: reported results
  source text: First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency • First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per share include $15 million expense, or $(0.05) per share, for acquired in-process research and development (IPR&D) and milestones • First quarter 2024 net income of $201 million and Adjusted EBITDA (non-GAAP) of $538 million • Full year 2024 financial guidance ranges affirmed
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/0001104659-24-056017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.